Note: Descriptions are shown in the official language in which they were submitted.
In view of the partial support provided by grants
from the United States Public Health Service and the
National Science Foundation in the making of the
present invention, the United states Government has
certain rights to this technology under 35 USC 202.
The present invention concerns a new class of
previously unreported linear and cyclic fragment
analogues of alpha-MSH, the method of stimulating
melanocytes in vertebrates by the appropriate
application of these analogues, and compositions
useful in the method.
In vertebrates, the color of their skin, fur, and
feathers is determined by the number and distribution
of certain color-bearing cells, e.g. melanocytes, the
number and distribution of which is under genetic
control. Melanocytes in mammals are localized at the
basal layer of the epidermis, at the dermal-epidermal
junction, and within hair follicles. Synthesis of
pigment (melanin~ within these melanocytes is con-
trolled by the activity of an enzyme, tyrosinase,
which is localized in an intracellular organelle, the
premelanosome. rJpon activation of tyrosinase, either
eumelanin (brown-black) or phaeomelanin (yellow-red)
pigment is deposited within the organelle; after
complete melanization, the premelanosome is known as a
melanosome, more specifically either an eumelanosome
or a phaeomelanosome depending upon color [see
Fitzpatrick, T. B., Y. Hori, K. Toda, M. Seiji, Jap.
J. Derm. 79:278~1969)~. Melanosomes are delivered to
surrounding keratinocytes of the skin or to cells
within the shaft of the growing hair by the process
known as cytocrine secretion.
Although melanin synthesis and pelage patterns
are expressed genetically, follicular melanogenesis
and pelage color changes in some mammals may be
hormonally cont:rolled by alpha-melanotropin (also
2 1~-~1)107
known as alpha-melanocyte stimulating hormone, i.e.
alpha-MSH), a linear tridecapeptide of the formula:
Ac-Ser-Tyr-Ser-Met-Glu-~is-Phe-Arg-Trp-Gly-Lys-Pro-
Val-NH2.
This hormone is derived from a large molecular weight
precursor protein, proopiomelanocortin, and is secreted by
the pars i~termedia of the pituitary gland, and
st~la~s melan~e adenylate cycla~ activity, tyrosin ~
activity, and subsequent melanin production ~see
Hadley, M. E., C. B. Heward, V. J. ~ruby, T. K.
Sawyer, and Y. C. S. Young, Pigment Cell 6:323(1980)J.
In humans, alpha-MS~ is apparently found only in
the pitui~y gland of the fetNs and not in ~e adult pit~i~y gland.
In adult humans, a certain level of melanin production
is genetically determined and constitutively present.
Variable melanin synthesis above and beyond this
baseline level is directly dependent on UV stimu-
lation, e.g. sunlight; exposure to high levels of sun
triggers increased production of melanin, with con-
comittant darkening of the skin. This response may be
an evolutionary adaptation to protect the person
against the aging and mutagenic properties of W.
Exposure to low levels of UV results in lower levels
of integumental melanin synthesis, fading of skin
color, and a diminished blocking effect allowing the
skin to absorb greater amounts of radiation. Although
adults do not synthesize alpha-MSH in the pituitary
gland, human melanocytes will respond to this hormone
(and a racemized preparation thereof).
Hypopigmentation of the skin in humans results
from local defects in melanin production within the
melanocytes, however, the etiology for many such
hypopigmentary disturbances is still unknown.
3 1~401~7
It is estimated that approximately 1% of the
world's population is afflicted with some form of
hypopigmentation dysfunctions. Although it is known
that alpha-MSH and certain analogues of alpha-MSH can
cause darkening in amphibians when administered
subcutaneously, and that alpha-MSH is associated with
skin darkening in adrenalectomized humans when
administered intramuscularly [Lerner, A. B., and J. S.
McGuire, N. E. J. Med. 270:539-546(1964)], these
routes of administration are not suitable for repeated
application necessary to achieve and maintain the
desired effect. Prior to the present invention no
adequate means of treating these hypopigmentation
disorders were known.
It has now been discovered that certain analogues
of alpha-MSH can effectively be adrninistered
transcutaneously, and these compounds will reach the
melanocytes in active form to stimulate the production
of melanin. ~hus~ according to the present invention,
it now may be p~ss~le and convenient to apply topical or other
compositions comprising alpha-MSH analogues to achieve
normalization of hypopigmentation dysfunctions such as
postinflammatory hypopigmentation, including
pityriasis, alba, tinea versiocolor, vitiligo,
idiopathic quttate hypomelanosis, and nevus
depigmentosus. Furthermore, it may now be possible to
achieve darkening of grey hair due to aging by topical
application of alpha-MSH analogues. It is also
possible to enhance the value of cornmercial animal
pelts by darkening via topical application of these
analogues. In addition, it is now possible to achieve
darkening of the skin in the total absence of sun or
W light irradiat:ion.
All previous studies of the peptides related to
alpha-MS~ isolated from the pituitary gland showed the
conservation of the Met4-Glu5-~is6-Phe7-Arg8-Trp9-
0 7
Gly10 sequence ~that is Methlonine-Glutamlc Acld-81--
tidine-Phenylalanlne-Arginlne-~ryptophan-Glyclne) a~
the common actlve core. Thl~ heptapeptlde sequence
has been suqqested to be t~e active slte of thc
hormones derived from proopiomelanocortin.
Based upon the structural relation~hip of alpha-
MSH (and its analogues and fragments) to its biologi-
cal potency, using the in vltro frog skin bioassay
system, the actl~e site of alpha-MSH appear~ to be the
common active core sequence of suitably modified
Ac-Met-Glu-~is-Phe-Arg-Trp-Gly-N~2. Thi~ fragment
~Alpha-MS~4 10) ha~ been synthesized ant tested for
it~ melanocyte stimulating activity in frog s~in and
shown to be a weak agonist when compared to the native
hormone. Thc a~ino acid exchanges ln position 5(Glu)
and lO(Gly1 have not, previou~ to the making of the
pre-~ent invention, been investigated. From previou~
researc~ tsee ~nited StateR Patents No~ 57,86~ and
4,485,039, and Canadian Patent ~pplication S.~.528,829
filed Fe~. 3, 1987) from which the pre~entinvention find~
its basi-, it was found that the replacement of
methionine with norleucine in the active linear core
heptapeptide gave a potent analogue of alpha-MS~. In
addition, substitution of phenylanine at position 7
with its enantlomer D-phenylalanine, resulted in a
more biologically potent analogue having prolonged
activity in both recognized (frog and lizard skin~
bioassays. The following table summarizes some of
these studies.
~ t~ ~
Selective F:ragments of Alpha-MSH an~:1 Their
Biological Activities on Frog (Rana pipiens)
Skin anc Lizard (Anolis carclinensis) Skin
Peptide Relative Potency
Frog Lizard
alpha-MSH 1.0 l.0
Ac [Nle4 D-Ph~7]-alpha -MSHl_13NH2
Ac-alpha -MSH4_10NH2 0.0003 0.004
4 0.(~02 0.06
Ac-[Nle ~-alp~a-MSH4_10NH2
Ac-[Nle l-alF,~a-MSH4 11NH2 0.t)0 ? 1 .0
[Nl 4 D-ph~7]-alpha-MsH4-lo 2 10.0
Ac-[Nle4,D-Phe ]-alpha-MSH4_11NH2 0.16 8.0
The investil~ation of these structural-activity
relationships showed two important factors: (1) the
replacement c~~ the Met amino ~cid with its oxidizable
side chain w:th oxi.datively stable amino acid Nle,
which is also an isostere for Me., resulted in about
:lO times enhar~cement of the bioloqica:l activity of the
peptide frag~ent; and ~2) replacement of L-Phe in
position 7 w.ith D-Phe and keeping Lys in position 11
further enhances the bioloqical. activity of the
alpha-MSH.
6 13~0107
In addition to the studies conducted on linear
alpha-MSR analogues, a number of conformationally
constrained alpha--MSH compounds have been synthesized
and tested for bi ~ ical potency. The first analogue
studied was Ac[Cys4,Cysl0]-alpha-MSHl l3NH2 which had
about lO to 20 times the activity of the native
alpha-MSH hormone in the frog skin bioassay and about
two-fold the potency of alpha-MSH in the lizard skin
bioassay. The design and synthesis of these prior
cyclic alpha-MSH: analogues were based on the
consideration of 1:he beta-turn structure at the center
of the active core (His -Phe7-Arg8-Trp9) of alpha-MSH,
and the importance of this conformation pattern for
biological activity.
From structure activity studies of
this cyclic clac;s of alpha-MSH analogues, several
conclusions were drawn: l) cyclization between
positions 4 (Met) and lO (Gly) by isosteric replace-
ment with cysteine amino acid enhanced the melanocyte
dispersion activity by not less than lO times in frog
skin bioassay and two times in lizard skin; 2) substi-
tution of Phe7 w:ith D-Phe7 in these cyclic analogues
causes double activity in frog skin and four times in
lizard skin bio,~ssay; 3) the presence of Lys in
position ll alwa.ys gave more active analogues than
those without it; and 4) reduction or expansion of the
ring size of disulfide bridge from 23-membered ring
causes severe reduction in the biological potency of
the resultant ana.logues.
The results of these studies with cyclic alpha-
MSH analogues are given in the following table:
1 0 7
Relative in Vitro Potencies of Cyclic Alpha-MSH
Analogues in the Frog and Lizard Skin Bioassays
Potency
Peptide Analogue Frog Lizard
Amino Acids Substitution Effect
alpha-MSH 1.0 1.0
tCIs4 Cys10~-alpha-MSH1_13NH210.0 2.0
[c r 4 Cys10]-alpha-MSH4_13NH2 0.6
Ac-[Cys , D-Phe7, Cys10]-alpha-
_13NH2 6.0 6.0
Ac-~Cys , Cys ]-alpha-MSH4 12NH210-0 1.5
Ac-[Cys4~ D-Phe7~ Cys10~-alpha-
MSH4-12NH2 20.0 6.0
Ac-[Cys , Cys ]-alpha-MSH4 11NH20.16 0.07
Ac [Cls4 D Phe7 cyslO~ alpha
MSH4-11NH2 2.5 3.0
Ac-[Cys4, cys1O]-alpha-MSH4 1oN~2 0.06 0.003
Ac-lCys4, D-Phe7, Cys10]-alpha-
MSH4_l0NH2 0.75 0.5
Ac-[Cys , Cys ]-cllpha-MSH4 13NH2 30.0 0.60
[Mpa , cy51 ]-alpha MSH4 13NH230.0 1.0
[Maa , Cys ]-alplla-MSH4 13NH20.06 0.06
Ac_[Hcy4, cys4]-a:lpha-MsH4-l3NH2 0.06 0.70
13 1~107
Biological potencies are measured relative to alpha-
MSH over the lin,ear portion of the dose-response
curve.
Maa = 2-Mercapto,acetic acid
Mpa = 3-Mercapto!propionic acid
Hcy = Homocystei:ne
To further investigate the structure-potency
relationship of alpha-MS~4 10 fragments, we have
systematically investigated the structural requirement
for melanotropic activity of a ,number of previously
unreported linear alpha-~SH4_l0 and 4-13 ogu
sis on the effect of substitution at positions 5 and
10 .
Based on the results obtained for linear alpha-
MSH analogues, we next investigated a different kind
of conformationally restricted alpha-MSH analogue.
Briefly, we made ,and concentrated on 4-10 (and 4-13)
fragments of alpha-MSH with the ge~eral structure:
Ac-[Nle -Xxx , D-Phe , Yyy ]-alpha-MSH4 lo~H2
where Xxx amino acid is either glutamic acid (Glu) or
aspartic acid lAsp) (that is one of the mono amino
dicarboxylic acidc,), and wherein Yyy amino acid is a
basic amino acid, lysine, ornithine, 2,4-
diaminobutyric acid (Dab), or 2,3-diaminopropionic
acid (Dpr). The Ac-alpha-MSH4_l0 linear analogues
listed in the following tables ~ere synthesized by
solid-phase peptide synthetic methods using
p-methylbenzy:Lhydrylamine resin as a solid support, and
purified by methods related to those used previously
for alpha-melanotIopin and analogues.
1 3 ~ 7
r~ Z ~ Zl Z
Z
,
~, o,
o ; ; ~ .
~1 ~1
O' ~1 U~ ~ ~ ~ ~ Z Z Z Z Z Z Z Z
~ u~ q C C .q .a ~, z z
~ ~ O O ~ a c~
r ~ ~ >, >,
C t~
.,~ C ~ t~ ~ n ~ rJ~ ~ tn ~ ~ cr~
C ~C ~ ~C ~ C ~C ~C tr~ 'n
-- o ~C ~ cC
:~ r,~ ~ al ~1 al c:l al al al al c~l al al C~
.~ ~
~ ~ rn u~ un rn rn rn rn In un rn rn u~ rn rq rn
0~ 1 1 1 1 1 1 1 1 1 ~
rn ~ u~ u~ ~ rn _l rn _l n un _~ u~
~: y r~ IC y IC ~: ~ IC y IC y ~IC ~IS ~ ~:
.ZZZ:ZZZZZZZZZZ
r ~ r,~ U ~ r~ r l r,,~
CC lCC lcc ~ C ~C ~ C ~C ~'S rS 1~5
~ v~ rf~ r~
11 1
-~ ~ h
' -l E~ E~ E~
l~ I I I
rn r
~S ~S ~S
O
~ ~ o r~ o_~
134010~
C~l ~
Z Z
~ ~,
r~
N r-l N et
z q z r~
Z Z ~ ~
o o o o
r~
S ~ S
~n r n ~_ N Z I P:~ :C X 1
t~ ~ Or~ Z ~q Z qU~
Z ~'.,, O ~ O ~ ~
O 1 ~1 ~ I Z
S ~ S ~ r~ o
~ ~ S ~ S r ~
~ ~ ~n ~r~n ~ ~ N d'
q ~ rc ~C
~1 1 1 1 I Z
S ~r,~ O
~I ~ ~ C~ ~ ~ O S O S O C ~
,~ rn ~ rn ~ ~: r ~ ~ ~ S
~ ~ /~ ~ ~ I O I ~ ~ q ~1
o ~ o ~ ~ o ~ o ~ o ~ ~ I
r- ~ t' r~ ~ r~ ~ r~ .~r~ r~
~ rna) rn ~ ~ ~n a~ R a~ ~ S O
c :~s' :~ ~ 51 :~ 5~ ~ s' ta s ~ h ~
o ~ a ~:4 p. ~ rn
,~ I I I I I I I ~ ~
al ~ ~1 al ~ al ~ al ~ Cl al I
~: r~ r~ r~ r~
51 Ltl S' 1.~ Ln S' Ln 1~ Ln S' Ln Ln ~ ~r~
rn ~..
rn I rn rn I ~n I ~n I rn tn ~, r~
al ~ al ~ ~ al ,¢ al ~ al ~ r¢
z z z; ~ z z; z z z z z z z z
L~ I I I I I I I I I I I I I I
r~ r~) rJ o ~ ~.) U U ~ u C)
~ r~ r¢ ~ r¢ ~ r¢ r¢ r¢ ~ r¢
.
~ ~ rY~ er Ln ~ r c~ c~ o ~ ~ ~ r Ln
o .l n 7
The linear analogues of alpha-MSH fragments were
manufactured according to the following example:
EXAMPLE I
Ac-[Nle4, D-Phe7, Lysl0, Glyll]-alpha-MsHl 13NH2
This compound was prepared by coupling N -Boc-Val
(the term "Boc~ means t-butyloxycarbonyl) to
p-methylbenzhydrylamine resin (2.0 g pMBHA resin, 0.7
mmol NH2/g of resin) using 3 fold excess of amino acid
using solid-phase methods of peptide synthesis. After
90 min the resin washed with dichloromethane, neutral-
ized and the amino group acetylated with acetic
anhydride-pyridine mixture. No reactive amino groups
on the resin were detected by the ninhydrin test after
30 min. A cycle for coupling of each amino acid
residue into the growing peptide chain consisted of
the following: l) Washing with four 30-ml portions of
CR2Cl2, 2 min/wash; 2) Cleavage of the Boc group by
30 ml of 48% trifluoroacetic acid in dichloromethane
containing 2% anisole, one treatment for 5 min, a
second for 20 min; 3) Washing with four 30-ml
portions of ~ichloromethane, 2 min/wash; 4)
neutralization by addition of two 30-ml portions of
10% diisopropylethylamine in dichloromethane and
shaking for 2 min each; 5) Washing with four 30-ml
portions of dichloromethane, 2 min/wash; 6) Addition
of 3-fold ex(ess of the Boc amino derivative (in this
case 2.1 mmol) in 5 ml of dichloromethane, 2.4
equivalents of N-hydroxybenzotriazole of 1 mmol/ml
solution of HOBt in DMF (except in the case of
N-Boc-N Tos His), (the term ~N Tos" means N-imidizol
tosyl), followed by 2.4 equivalents of DCC of
mmol/ml solution of DCC in DMF. The mixture then
shook for 2-3 h (in case of Trp, Ar~, and ~is, DMF was
12 13-~ 0 107
used as a coupling solvent); 7) After completion of
the coupling ~ninhydrin negative) washing with three
30-ml portions of dichloromethane, 2 min/wash; 8)
washing with 3 ml portion of 100% ethanol, 2 min/wash;
9) Washing with four 30-ml portions of
dichloromethane, 1 min/wash. The protected peptide
resin corresponding to the title compound was obtained
after stepwise coupling of the following N -Boc amino
acids (or derivatives) was performed (in order of
addition): N -~oc-Prog N -Boc-Gly, N -Boc-Lys-(N
ClZ); N~~ -Boc-N -For-Trp, N -Boc-Ng-Tos-Arg, N
-Boc-D-Phe, N-~-Boc-N -Tos-~is (the term ~Ngn means
N-guanidino; ~N means N-indolyl, and -n2ClZ" means 2-
chloro~Pnzylox~carbonyl. The resultinq
Boc-His(Nim-Tos)-~-Phe-Arg(Ng-Tos)-Trp (N -For)-Lys(N~
-2ClZ)-Gly-Pro-Val-p-MBHA resin was divided into four
portions. O~e-quarter (1.0g 0.5 mmol) of the
protected peptide--resin was converted to the protected
title peptide resin after coupling N-
~-Boc-r-Bzl-Glu, N -Boc-Nle, N -Boc-Ser (0-Bzl), N-
~-Boc-Tyr(0-2 BrZ); N -Boc-Ser(0-Bzl)(the term n 2BrZ
means 2-bromo-benzyloxycarbonyl). After coupling the
last amino a~id, the N -Boc protecting group was
removed, the amino group neutralized, and the
protected peptide was N -acetylated with a 10-fold
excess of N-acetyl-imidazole in 20ml of dichloro-
methane and the resulting protected peptide resin,
Ac-Ser-(0-Bzl~-Tyr(0-2-BrZ)-Ser(0-Bzl)-Nle-Glu( ~-Bzl)
-His(N m-Tos)-D-Phe-Arg(Ng-Tos)-Trp(N -For)-Lys (N
-2-ClZ)-Gly-Pro-Val-p-MBHA resin, dried in vacuo. The
protected peptide resin (1.0 g) was cleaved from the
resin by liquid HF. After evaporation of the volatile
materials in vacuo at 0~C, the dried product was
washed with ethyl ether (3 x 30 ml), extracted with
30~ aqueous HOAc (3 x 30 ml), and lyophilized. The
peptide powder (530 mg) was divided into two portions
1~40107
13
(260 mg each) and one portion was dissolved in 1.5 ml
of ammonium acetate buffer (pH 4.5), filtered through
a cartridge fi:lter into the top of a CMC column (2.0
x 30.0 cm) and eluted using 250 ml each of O.OlM (pH
4.5), O.lM (pH 6.8), and 0.2M (pH 6.8) NH40Ac. The
major peak detected at 280 nm, was eluted between the
end of the 0.1 and the first half of the 0.2 M NH40Ac
fraction and was lyophilized to give 142.3 mg of white
powder. 80.0 mg of the peptide powder was purified ~y
preparative HPLC and the major peak collected and
lyophilized to give 63 mg of the title peptide.
14 ~3~0107
EXAMPLE II
Ac-[Nle , Asp , D-Phe , Lys ' Gly ~-alpha-MSHl 13NH2
This compound was prepared from 1.0g ( 0.5 mmol)
of N~Boc-His(Nim-Tos)-D-Phe-Arg (Ng-Tos)-Trp (N -For)-
Lys (N~-2-ClZ)-Gly-Pro-Val-p-MBHA resin by stepwise
coupling of N ~ -Boc-Asp( ~-Bzl), N~~-Boc-Nle, N
-Boc-Ser(0-BZl), ~-Boc-Tyr(0-2-BrZ), ~ oc-Ser(0-Bzl).
Each coupling was achieved by the same approach
mentioned previously. Acetylation of the protected
tridecapapeptide-resin was carried out by 10-fold
excess of N-acetylimidazole in dichloromethane (5 h)
after deprotection and neutralization of N-terminal
Boc group. The Ac-Ser(0-Bzl)-Tyr(0-2-BrZ)-Ser(0-BZl)-
Nle-Asp(~-Bzl)-His(N ~ os)-D-Phe-Arg (Ng-Tos)-Trp
(Ni-For)-Lys(N -2-ClZ)-Gly-Pro-Val-p-MBHA resin was
dried in vacuo to give 1.8 g of protected peptide
resin. A 1.0 g of the protected peptide resin was
cleaved by liquid HF and upon evaporation of the
volatile materials, washed with diethylether (3 x 30
ml), the peptide extracted with 30% aqueous HOAc l3 x
ml), and lyophilized. A portion of the crude
tridecapeptide (200 mg) was dissolved in 1.5 ml of
NH40Ac buffer (pH 4.5), filtered through a cartridge
filter into the top of the CMC column (2.0 x 30.0 cm)
and eluted with the same sequence of the discontinuous
gradient of ~40Ac as mentioned in Example I. The
separated peptide after lyophilization was 152 mg. A
100 mg of this crude peptide was further purified by
HPLC to give 67 mg of the title peptide.
1~ ~0107
EXAMPLE I I I
Ac- [N e9, D-Phe7, Lysl~, Glyl1]-a pna-MSH4 l3NH2
From ] . O g (O . 5 mmol) of Boc-His (N m-Tos) -D-Phe-
Arg (Ng-Tos) -TrF (Ni-For) -Lys (Ne-2 -ClZ) -Gly-Pro-Val-p-MBHA
resin the title peptide was synthesized by solid-phase
technique after stepwise eoupling of N~-Boc-Glu (~-Bzl),
and N~-Boc-Nle. Each coupling --eaetion was aehieved in
the previous examples exeept that the af-etylation of the
N-terminous was aehieved by 2-fold exeess of 1:1 acetic
anhydride-p-yricline in diehloromethane for 1 h. The
peptide 4 was obtained in purif-ied form as outlined in
Example II _o qive a white powdl-r with a yield of 22%.
16 13-ln1~7
EXAMPLE IV
Ac-~Nle , Asp , D-Phe , Lys , Gly l]-alpha-MSH4 13NH~
From 1.0 g ( 0.5 mmol) of Boc-His(N -Tos)-D-
Phe-Arg(Ng-Tos)-Trp(N -For)-Lys(N -2-ClZ)-Gly-Pro-Val-
p-MBHA resin prepared as in Example I, the title
peptide was prepared by stepwise coupling of N~~
-Boc-Asp ~ -Bzl), and N~-Boc-Nle. The same technique
was used as described in Example I in processing the
resulting protective peptide resin. The desired
peptide yielded 53 mg of HPLC pure peptide starting
with 130 mg of crude peptide purified previously with
CMC chromotography as outlined in Example I.
17 i 3~ 0~ ~ 7
EXAMPLE V
Ac[Nle4, !~-Phe7, Lys10~-alpha-MSH4 1oNH2
A 2.7 g resin of p-methylbenzhydrylamine (0.7
mmol NH2/g resin) was suspended in dichloromethane and
washed three times with 30 ml portions of dichloro-
methane. The washed resin was then shaken for 2 h in
dichloromethane before filtering out the solvent. The
swelled MBHA resin was neutralized and coupled with
the amino acids as outlined in Example I. The
following amino acid derivatives were coupled into the
resin (in order of their coupling): N-~-Boc- Lys(N~
-2-ClZ), N -Boc-Trp (N -For)! N -Boc-Arg(Ng-Tos), N
-Boc-D-Phe, N ~ -Boc-His (N -Tos). The resulting
Boc-His(Nim-Tos)-~-Phe-Arg(Ng-Tos)-Trp(N -For)-Lys(N~~
-2-ClZ)-p-MBHA resin was divided into two portAions.
One part of th~? resin was coupled ln stepwise fashion: N~
-Boc-Glu(~-Bzl) and N~-80c-Nle. The finished peptide
resin was deboxylated and the N-terminal acetylated
with 2-fold excess of 1:1 mixture of acetic
anhydride-pyridine in dichloromethane for l h. The
finished protected peptide resin was washed with
dichloromethane and dried in vacuo to give 2.1 g. A
1.7 g of the protected peptide resin was cleaved by
anhydrous liquid lIF-anisole-dithioethane (17 ml HF, 2
ml anisole, 1 ml dithioethane). After evaporation of
the volatile materials, the dried, cleaved peptide was
washed with 3 x :30 ml of anhydrous diethylether and
extracted with 3 x 30 ml of 30% aqueous HOAc. The
aqueous extract of the peptide lyophilized to give 700
mg of crude pept:ide. A 300 mg sample of the crude
peptide was dissolved in 2 ml of NH40Ac buffer (pH
4.5), and filtered through a cartridge filter on the
top of CMC column. The major peak was collected and
lyophilized tc give 172 mg of white powder peptide.
~3 -~0~.07
18
110 mg of th~ crude peptide was purified on HPLC to
give 50 mg of pure title peptide.
n7
19
EXAMPLE VI
Ac- ~le4rAsp , D-Phe, Lys ~-alpha-MSH4 1oNH2
The protected peptide resin to the title compound
was prepared from 1.8 g of Boc-~is(N -Tos)-D-Phe-Arg-
(Ng-Tos)-Trp(N -For)-Lys(N~-2-ClZ)-p-MBHA by stepwise
coupling of N -Boc-Asp ~ -Bzl), and N -Boc-Nle. Each
coupling reaction was achie~ed with a 3-fold excess of
N~-Boc amino acid (or derivative), a 2.4-fold excess
of DCC, and a 2.4 fold excess of HOBt following the
same strategy outlined previously. After coupling the
last amino acid, the N ~-Boc protection group was
removed, the amino group neutralized, and acetylated
with 2-fold excess of 1:1 mixture of acetic
anhydride pyridine in dichloromethane for 1 h. The
Ac-Nle-Asp ~ -Bzl)-His(N -Tos)-D-Phe-Arg(Ng-Tos)-Trp-
(N -For)-Lys(N~-2-ClZ)-p-MBHA resin was washed with
dichloromethane and dried in vacuo to give 2.1 g. A
1.5 g sample of the protected peptide resin was
cleaved by liquid RF and processed as in Example V to
give 64 mg of the title peptide after HPLC
purification of 112 mg of CMC chromotographically pure
pept ide .
~34010~
EXAMPLE VII
Ac-[Nle4, Asp5, D-Phe7, Dab10]-alpha-MSH4 1oNH2
The protected peptide resin to the title compound
was synthesized as Example V except the N -Boc-Dab(N
-Z~ and N -Boc-Asp ~-Bzl) were used instead of N -Boc-
Lys~ -2CLZ) and N -Boc-Glu(~-Bzl), respectively, in
the coupling scheme to give Ac-Nle-Asp ~-Bzl)-His-
(N -Tos)-D-Phe-Arg(Ng-Tos)-Trp(N -For)-Dab(N~-Z)-p-
MBHA resin. Upon cleaving and processing the peptide
resin as reported for Example V, the peptide 12 was
obtained as a white powder in 36~ yield.
2 ~ 3 1 ~J 7
EXAMPLE VIII
Ac-[Nle4, Asp5, D-Phe7, Dpr10~-alpha-MSH4 1oNH2
The protected peptide resin to the title compound
was synthesized as in Example V with the exception
that N -Boc-D~r(~ -Z) was used instead of N -80c-Lys
(N -2-ClZ~ and N -Boc-Asp ~-Bzl) for N -Boc-Glu~Y-Bzl)
in the coupling scheme to give Ac-Nle-Asp ~ -Bzl)-His-
(N -Tos)-D-Phe-Arg(Ng-Tos)-Trp(Ni-For)-Dpr( ~-z)-p-
MBHA resin. The peptide was cleaved from the resin,and processed as Example V to give the desired peptide
as a white powder: yield 36~.
1~ ~0107
EXAMPLE l:X
Ac-[Nle4, Lys1~]-alpha-MSH4,0NH2
The protected peptide res_.n to the title compound
was synthesiz~d as reported i.n Example V, with the
exception that N~-Boc-Phe was used instead of N~-Boc-D-
Phe in the coupling scheme to give Ac-Nle-Glu(~-Bzl)-
His(Nim-Tos)-Phe-Arg(Ng-Tos)-Trp(Ni-For)-Lys-(N~-2-ClZ)-p-
MBHA resin. The peptide was cleaved and processed 7 to
give the t.itle compound with 40~ yield.
X'
~340107
EXAMPLE X
Ac [Nle~, Asps, Lys'C]-alpha-MSH4l0NH2
The protecled peptide resin to the title compound
was synthes:~zed as reported ir. Example V, with the
exception that N~-Boc-Phe was used instead of N~-Boc-D-
Phe and N~-Bcc-A,p(~-Bzl) was replaced N'~-Boc-Glu(~-Bzl)
in the coup~ing scheme to give Ac-Nle--Asp(~-Bzl)-Phe-
Arg(Ng-Tos)-~lrp(Ni-For)-Lys(N'~-2-(~lZ)-p-MBHA resin. The
peptide was cleaved from the resin, the protecting groups
removed, an(1 the title compound purified as previously
reported to give the product as a white powder in 37
yield.
24 ~ lQ7
The biol~gical potencies for the linear analogues
made in accordance with the preceding examples are
given in the following table in which ~P~ indicates
prolonged action (~1~ = yes, n_n = No) and ~ND"
indicates the sample was not run for the specific
test.
Biological Potency Residual Activity
Analogue Frog Lizard Frog Lizard
~-MSH 1.0 1.0 P~-) P(-)
2 6.0 8.0 P(~) p(-)
3 9.0 8.0 Pt+) P(-)
4 0.8 8.0 P(+) P(~)
1.0 10.0 P(+) P(+)
6 0.1 8.0 P(-) P~-)
7 0.2 8.0 P(-) P(-)
8 0.7 8.0 P(-) P(-)
9 0.6 8.0 P(-) P(-)
0.9 10.0 ND P(-)
11 0.9 10.0 P(+) P(+)
12 0.9 50.0 P(-) P(-)
13 0.2 8.0 Pl-) P(-)
14 0.001 0.08 P(+) P(-)
0.004 0.08 P(+) P(-)
The res~lts obtained with the linear conforma-
tionally restricted alpha-MSH analogues led to inves-
tigations using a different kind of restricted ana-
logue, conformationally restricted cyclic alpha-MSH
analogues.
The solid-phase peptide synthesis of cyclic
melanotropin peptide analogues were conducted by
conventional so].id-phase synthetic techniques. ~n
summary, N ~~-tert-butyloxycarbonyl ~Boc) protected
1~4~1Q7
amino acids and their derivatives were coupled to a
p-methylbenzhydrylamine resin with a 3-fold excess of
the Boc-protected amino acid derivative, a 2.4-fold
excess of N-hydroxybenzotriazole (HOBt) of 1 mmol/ml
solution in DMF (except in case of His~, and a 2.4-
fold excess of 1 mmol/ml solution of dicyclohexylcar-
bodiimide ~DCC) in DMF. The coupling reaction was
carried out in dichloromethane for a 1 to 3 hour
period, which ~ere monitored by ninhydrin and/or
chloranil tests and repeated as necessary. Reactive
side chains of amino acids were protected as follows:
Lys 2,4-dichlorobenzyloxycarbonyl; Orn, Dab, and Dpr
benzyloxycarbony~; Trp, formyl; Arg, tosyl; His,
tosyl; Glu and Asp, Benzyl ester. Cleavage of the N
-Boc protecting yroup was performed by treatment with
48% trifluoroacetic acid containing 2~ anisole in
dichloromethane for 5 and 20 min each.
A cycle for the incorporation of each amino acid
residue into the growing peptide chain consists of the
following: t ) washing with CH2C12 (4 x 30 ml,
min/wash), 2) Boc protection was removed at each step
by two treatments with 48% TFA in CH2C12 containing 2~
anisole for 5 and 20 min each; 3) washing with CH2C12
(2 x 30 ml); ~ neutralizing with 10% diisopropylethyl-
amine in CH2C12 (2 x 30 ml, 3 min/wash), 5) washing
with CH2C12 (3 x 30 ml, 2 min/wash1, 6) adding the
Boc-protected amino acid derivative in 20 ml CH2C12
(except in the cases of Trp, Arg, and His when DMF was
substituted for CH2C12 because of the solubility
problem), followed by ROBt, followed by DCC and
shaking for 1-3 h; 7) washing with CH2C12 (3 x 30 ml,
2 min/wash); and 8) washing with 100% EtOH (3 x 30 ml,
2 min/wash). Completion of coupling was monitored,
and after coupling the last amino acid, the N~~-Boc
protecting group was removed, the amino group
neutralized, and acetylated with a 10-fold excess of
26 ~ 107
N-acetylimidazole in CH2C12 or using 1:1 mixture of
acetic anhydride pyridine in CR2C12 (2-fold excess
for 1 h).
Peptides were deprotected and removed from the
resin with anhydrous liquid HF (10 ml/1 g of resin)
containing 10% anisole and 8% 1,2-dithioethane at 0~C
for 45 min. After evaporation of the volatile
materials _ vacuo, the free peptides were washed with
diethyl ether or ethyl acetate (3 x 30 ml) and then
extracted with 30~ aqueous solution of acetic acid ~3
x 30ml), and distilled water (3 x 30 ml). The
combined aqueous extract was lyophilized to give a
white powder of the crude peptide. Each peptide was
purified by column chromatography on cation-exchange
carboxymethyl cellulose ~CMC) resin, using
discontinuous gradient of ammonium acetate buffer as
follows: 250 ml of O.OlM NH40Ac(pH 4.5), 250 ml of
0.01 M NH40Ac(pH 6.8), 250 ml of 0.1 M NH40Ac(pH 6.8),
and 250 ml of 0.2 M NH40Ac (pH 6.8). The major peak
(280 nm detection) eluted during the last part of 0.01
M NH40Ac (pH 6.81 and the first half of the 0.1 M
NH40Ac (pH 6.8) buffer was lyophilized to give a
purified peptide as a white powder.
The structure of the cyclic alpha-melanotropin
analogues which comprise a portion of the present
invention are set forth in the following table.
27 1~ 10107
N :C
~: Z
~Z ~
~ I ~4
Z
0 ~
aJ ~ O ~ Z Z Z Z Z
O O o o o
Z Z Z Z Z
C I ~ :~ r~ ~ ~ 'O ~C~
C ~ ~ n O O O O O O
,c ~ s ~ s s o ~ ~ ~ o a a
a c~ al al a~
_, ~I I I I I I I ~ ~ ~ s ~ s
c ~ al a a a a al
O -- Z Z Z Z Z Z ~ ' ' ' ' '
u ~ 0 ~ ~
,rZ Z Z Z Z Z
_ I I I I I I
~ I
U~
O I r~ 0 a~ o _I N ~ ~ ~-1 ~ ~ ~ ~
28 1~ ~f!107
The peptide analogues according to the present
invention are prepared according to the following
examples:
EXAMPLE XI
Ac-[Nle4, Glu5, D-Phe7, Lys10, Glyll]_Alpha_MsH4 13NH2
Starting with 1.0 g of N -Boc-Val-p-MbHA resin
(0.7 mmol of N -Boc-Val), the protected peptide resin
for the title compound was prepared after stepwise
coupling of the following N -Boc-protected amino acids
(in order of addition): N -Boc-Pro; N -Boc-Gly; N
-Boc-Lys(N -2,4-CL2Z); ~-Boc-Trp(N -For); N -Boc-Arg-
(Ng-Tos); N -Boc-D-Phe; N -Boc-His(Ni -Tos); N~~-
Boc-Glu(~-Bzl); N -Boc-Nle. After coupling the last
amino acid, the N ~ oc protecting group was removed,
the amino group neutralized, and acetylated with
either 10-fold excess of N-acetylimidazole in
dichloromethane (6-8 h) or with 2-fold excess of 1:1
mixture of acetic anhydride:pyridine in
dichloromethane (1-2 h), and the resulting protected
peptide resin
Ac-Nle-Glu( ~-Bzll-RistN -Tos)-D-Phe-Arg~Ng-Tos)-Trp-
(Ni-For)-Lys(N -2,4-ClZ)-Gly-Pro-Val-p-MBHA. A 1.0 g
(0.6 mmol) portion of the protected peptide resin was
treated with 10 ml anhydrous HF in the presence of 1
ml anisole and 0.8 ml 1,2-dithioethane for 45 min at
0~C. After the HF, anisole, and l,2-dithioethane were
evaporated in vacuo, the dried product mixture was
washed with three 30 ml portions of diethylether, and
the peptide was extracted with three 30 ml portions of
30% acetic acid. Then, upon lyohilization of the
aqueous extract of the peptide, a 325 mg of crude
Ac-Nle-Glu-His-D-phe-Arg-Trp -Lys{;ly-Pro-Val-NH2
peptide, as a white powder, was obtained. A 150 mg of
crude Ac-[Nle , D-Phe , Lys , Gly ]-alpha-MSH4 l3NH2
29 1~ ~ 0 107
was subjected to the purification scheme which
included dissolving the crude peptide in 2-4 ml of
0.01 M NH40Ac, pH 4.5, and chromatographed on
carboxymethylcellulose column ~2.0 x 25.0 cm) with a
discontinuous graclient (250 ml each) of 0.01 (pH 4.5),
0.01, and 0.2 M NH40Ac (pH 6.8). The major peak
detected at 280 nm was eluted during the first half of
the 0.1 M NH40Ac ~pH 6.8) buffer and was lyophilized
to give 104 mg of a white powder. The CMC pure Ac-
[Nle , D-Phe , Lys , Glyll]_alpha_MsH N~ was
further purified by HPLC, using 0.1% trifluoroactic
acid buffer and acetonitrile as organic modifier on
Vydac 218TP15-16 ~18RP ~25 cm x 25 mm) semipreparative
column. A 100 mg of the peptide was HPLC purified to
g e 74 mg pure A~-[Nle4~ D-Phe7 Lys10 Gl 11]
MSH4 ~3NH2 peptide; A 40 mg sample of pure Ac-[Nle ,
D-Phe , Lys , Gly ~-alpha-MSH4 13 was dissolved in 1
ml of S% HCl aqueous solution and chromatographed on
diethylaminoethylcellulose ~of hydrochloric acid form)
column (1.0 x 15 0 cm) with 100 ml of 5~ HCl aqueou~
solution and the eluted peak monitored at 280 nm.
Lyophilization o~ the collected peptide peak gave 35
mg of the Ac-~Nle, D-Phe7, Lys10, GlYll]~alPha~MSH4 1
NH2 x ~Cl salt. The peptide salt was dissolved in 3
ml of dry DMF and secondary amine free DMF (distilled
from ninhydrin under reduced pressure). To the
peptide solution in DMF was added anhydrous R2HP04,
the reaction mixture was cooled in an ice-salt bath to
0~C and 17~1 of diphenylphosphorylazide was added and
the reaction mixt:ure stirred at 0~C and then the whole
reaction flask transferred to the cold room at 12~C.
The reaction mixture was stirred overnight at 12~C and
the completion of the reaction was monitored by ~PLC
(Vydac column, 25.0 cm x 4.6 mm) with 0.1~ trifluoro-
acetic acid/C~3CN. Also, the ninhydrin test was used
to detect the completion of the cyclization. The
D * Trademark
1~ 10 107
Ac [Nle , Glu , D-Phe7, Lys10 Gly11] 1 ha
was purified, after quenching the reaction with 10%
aqueous HOAc solution, by desalting on P4 polyacryl
amide column (80.0 cm x 1.0 cm) using 30~ HOAc and
purified by semipreparative HPLC to qive 16 mg of
cyclic peptide Ac- [Nle , Glu , D-Phe , Lys
Gly ]-alpha-MSH4 13NH2.
31 1 ~ :~i~ O I O ~J
EXAMPLE XII
Ac-[Nle4, Glu5,D-Phe , Lys ]-alpha-MSH4 1oNH2
The title compound was prepared starting with 2.0
g of N~-Boc-Lys(N -2,4-C12Z)-p MBHA resin (1.0 mmol/g
of N~C-Boc-Lys(N -2,4,C12Z), the protected peptide
resin to the tit:Le compound was prepared after step-
wise coupling of the following N -Boc-protected amino
acids (in order vf addition): N -Boc-Trp~N -For); N~
-Boc-Arg(Ng-Tos); ~ -Boc-D-Phe; N -Boc-His(N m-Tos).
The resulting protected peptide resin, N -Boc-His
(N -Tos)-D-Phe-Arg(Ng-Tos)-Trp(N -For)-Lys(N
-2,4-C12Z)-p-MBHA resin was split into two halves. A
1.4 g ( 0.5 mmol) portion of the protected
pentapeptide-resin was converted to the protected
title peptide resin after coupling N -Boc-Glu( Y-BZ1)
and N -Boc-Nle. After coupling the last amino acid,
the N ~-Boc protecting group was remo~ed, the amino
group neutra~ized, and acetylated as reported in
Example XI to give the protected peptide resin
Ac-Nle-Glu(~-Bzl)-His(N -Tos)-D-Phe-Arg(Ng-Tos)-
Trp(N -For)-Lys(N -2,4,C12Z)-p-MBHA resin. A 1.0 g of
the protected peptide resin was subjected to liquid HF
cleavage and the peptide processed as in Example XI to
give 356 mg of the crude Ac-[Nle4, D-Phe7,
Lysl ]-alpha-MSH4 1oNH2 peptide as a white powder. A
100.0 mg of the crude peptide was subjected to the
purification scheme as outlined in Example XI to give
mg of HPLC pure Ac-]Nle4, D-Phe ,
Ly51 ]-alpha-MSH4 1oN~2 peptide. 40 mg of this pure
peptide was cyclized by the same approach as in
Example XI to give 13 mg of HPLC pure Ac-[Nle , Glu5,
D-Phe/, Lys10]-alpha-MSH4 1oNH2.
32 1~1C$107
EXAMPLE XIII
Ac-~Nle~, AspS, D-Phe, Lys10]-alpha-MSH4 1oNH4
From 1.4 q ~ O.S mmol) of Boc-HislNim-Tos)-D-
Phe-Arg~Ng-Tos)- l'rp(N -For)-Lys~N -2,4-C12Z)-p-MBH~
resin the protected peptide resin of the title com-
pound was prepared by stepwise coupling of N -Boc-
Asp ~-Bzl) and N -Boc-Nle. Each coupling reaction wae
achieved by following the same coupling scheme report-
ed under the general solid-phase peptide methodology.
After coupling the last amino acid, the N-~-Boc pro-
tecting group was removed, the amino group neutral-
ized, and acetylated as reported in Example XI, tc
give the protected peptide resin Ac-Nle-Asp ~-Bzl)
-His(N -Tos)-D-Phe-Arg(Ng-Tos)-Trp(N -For)-Lys(N~-2,
4-C12Z)-p-MBHA resin. A 1.O g sample of the vacuu~
dried peptide resi.n was cleaved and processed as in
Example XI to give 370 mg of the crude Ac-[Nle~, Asp5,
D-Phe7, Lys10}-alF)ha-MSH4 1oNR2. A portion of the
crude heptapeptide (110 mg) was purified by the same
procedure used in Example XI to give 82 mg of white
,~cwder of the lLnear pre ~ rsor of the titled peptide. A 40.0 mg
sa~ e of the F~re Ac-[Nle4, Asp5,D-Phe7, Lys10]-alpha-
MSH4 1oNH2 was s~jected to cyclization to qive, after
processing the HPLC' Purification, a yield of 12 mg of
pure Ac-[Nle4, AspS, D-Phe7, Lys10]-alpha-MSR4 1oNR2.
33 13~f~ 107
EXAMPLE XIV
Ac [Nle4 Asp5 D-Phe7, Ornl0]-alpha-MSH4_10N~2
A 1.0 g of p-MBHA resin (0.7 mmol/g) was loaded
with N -Boc-Orn(N~-Z) using the coupling scheme
reported in the general solid-phase procedure. After
1 h coupling the reaction stopped, the resin washed,
neutralized and the free amino group on the resin
acetylated with 2-fold excess of 1:1 mixture of acetic
anhydride:pyridine in dichloromethane for 1 h. Then
the following amino acids were successfully coupled to
the resin ~y stepwise coupling: N -Boc-Trp(N -For); N
-Boc-Arg(Ng-Tos); N -Boc-D-Phe; N ~ oc-His(N m-Tos); N
-Boc-Asp(~-Bzl); N -Boc-Nle. Each coupling reaction
was achieved by following the same coupling scheme
outlined under the general solid-phase peptide method-
ology. After coupling the last amino acid, the N -Boc
protecting group was removed, the N-terminal amino
group neutralized and acetylated to give the protected
peptide resin Ac-Nle-Asp ~-Bzl)-His (N -Tos)-D-Phe-
Arg (Ng-Tos}Trp~N -For)-Orn(N~-Z)-p-MBHA resin. A 1.O
g of the vacuum dried peptide resin was cleaved and
processed as outlined under Example XI to give 332 mg
of the crude Ac-[Nle4, Asp5, D-Phe7, Ornl03-alpha-
MSH4 10NH2 A 105 mg portion of the crude heptapeptide was
purified by the method used in Example XI to give 78
mg of white powder of the linear peptide. A 40.0 mg
sample of the pure Ac-[Nle , Asp , D-Phe7, Ornl0]-
alpha-MSH4 1oNH2 was exposed to the cyclization
procedure used for Example XI, to give, after proper
workup, 15 mg of pure Ac-[Nle4,
Asp5, D-Phe7, Ornl0]-alpha-MSH4 1oN~2.
34 ~ n7
EXAMPLE XV
Ac-[Nle4, Asp5, D-Phe7, Dab10]-alpha-MSH4 1oNH2
1.0 g of p-MBHA resin (0.7 mmol/g) was cou-
pled with N -Boc--Dab(N~-Z) using the coupling scheme
reported in the general solid-phase procedure. After
1 h coupling the reaction stopped, the resin washed,
neutralized and the unreacted amino group on the resin
acetylated with l-fold excess of 1:1 mixture of acetic
anhydride:pyridine in dichloromethane for l h. Then,
the following amino acids were successively coupled to
the resin by stepwise coupling: N -Boc-Trp(Ni-ForJ; N
-Boc-Arg(Ng-Tos); N -Boc-D-Phe; N -Boc-His(N m-Tos); N
-Boc-Asp(~-Bzl); and N - Boc-Nle. After coupling the
last amino acid, the N -Boc protecting group was
removed, the N-Terminal amino group neutralized, and
acetylated as reported in Example XI, to give the
protected peptide resin Ac-Nle-Asp(~ -Bzl)-His-
(Nim-Tos)-D-Phe-Arg(Ng-Tos)-Trp(N -For)-Dab(N -Z)-p-
MBHA resin. A 1.0 g of the vacuum dried peptide resin
was cleaved and processed to give 318.2 mg of the
crude Ac-[Nle4, Asp5, D-Phe~, Dab10]-alpha-
MSH4 1oNH2. A 100.0 mg of the crude heptapeptide waspurified to give 78.2 mg of white powder of the linear
peptide. A 4'~.0 mg portion of the pure Ac- ~le , Asp ,
D-Phe , Dab ]-alpha-MSH4 1oNH2 was cyclized and
purified as previously discussed to give 13.2 mg of
4 AlpS D-Phe7, Dàb10-alpha-MSH4_l0N~2.
1 0 7
EXAMPLE XVI
Ac-[Nle , Asp , D-Phe , Dpr ]-alpha-MSH4 1oNH2
A 1.0 g of p-MBHA resin (0.7 mmol/g) was coupled
with N~~-Boc-Dpr(N~ -Z) using the coupling scheme
reported in the general solid-phase procedure. After
1 h coupling the reaction stopped, the resin washed,
neutralized and the unreacted amino group on the resin
washed, neutralized and the unreacted amino group on
the resin acetylated with 2-fold excess of 1:1 mixture
of acetic anhydride:pyridine in dichloromethane for 1
h. Then the following amino acids were successively
coupled to the resin by stepwise coupling: N -Boc-
Trp(Ni-For); N -Boc-Arg(Ng-Tos); N -Boc-D-Phe; N
-Boc-His(N -Tos); N~C-Boc-Asp(~ -Bzl); ~-Boc-Nle.
After coupling the last amino acid, the N~~-Boc
protecting group was removed, the N-terminal amino
group neutralized, and acetylated as in Example XI to
give the protected peptide resin Ac-Nle-Asp ~ -Bzl)-His
(N -Tos)-D-Phe-Arg(Ng-Tos)-Trp(N -For)-Dpr ~
-Z)-p-MBHA resin. A 1.0 g of the vacuum dried peptide
resin was cleaved and processed as outlined urder 1 to
give 310.8 mg of the crude Ac-[Nle , Asp , D-Phe ,
Dpr ]-alpha-MSH4 1oNH2. A 115.0 mg portion of the crude
heptapeptide was purified according to the procedure
of Example XI to give 82.5 mg of white powder of the
linear peptide. A 38.3 mg of the pure Ac-[Nle4, Asp5,
D-Phe , Dpr 0]-alpha-MSH4 1oNH2 was cyclized and
~urified as previously discussed to give 11.3 mg of
4 Arp5 D-Phe7 Dpr1~]-alpha-MS~4_10NH2-
36 13401~7
~ he biological potencies of alpha-MSH, the
linear, and the cyclic analogues were determined by
their ability to stimulate melanosome dispersion in
vitro in the frog and lizard bioassays. These in
vitro assay provides clear cut dose response cur~es
(between 2.5 x 10 11 and 4 x 10 10 M) and can detect
minimal concentration of alpha-MSH of about 10 11 M.
The assay is based upon the centrifugal dispersion of
melanosomes (melanin granules) within the dendritic
processes of integumental dermal melanophores leading
to darkening of the skin. All the test solutions were
prepared via serial dilutions from a stock solution
(10 4 M). The frogs (Rans pipiens) used in these
evaluations were obtained from ~ons Scientific,
Germantown, Wl, and the lizards (Anolis carolinensis)
were from the Snake Farm, La Place, LA. Biological
activities of the cyclic alpha-melanotropin analogues
are reported in the following table:
Biological Potency Residual Activity
Analogue Frog Lizard Frog Lizard
a-MSH 1.0 1.0 p(-) p(-)
17 1.0 6.0 p(+) p~+)
18 0.5 9.0 p(+) p~+)
19 0.5 90.0 p(+) P(+)
1.0 20.0 p(-) p(-)
21 1.0 5.0 p(-) p(-)
22 0.01 5.0 p(-) p(-)
Our previous patents (4,457,864 and 4,485,039),
indicated the importance of conformational
restriction of the active site of alpha-MSH. Previous
cyclization ccnstraints of alpha-MSR at positions 4 and
using pseudoisosteric replacement of Met-4 and
r~
~ LJ
1~0107
Gly-10 with Cys amino acids resulted in many fold
enhancement in melanocyte dispersions activity of the
synthesized analo~ue. The potency enhancement of the
cyclic analogues compared to that of their linear
ancestor is clearly dependent on the bioassay system
used. Our major interest was to get analoques with
high potency on lizard skin since the activity of the
latter bioassay is linearly correlated to the activity
in the mammalian systems. The major characteristics
of [Cys4, Cysl0]-alpha-MSH cyclic analogues were that
they showed low activity in lizard skin bioassay and
high potency iII frog skin; also with 500-fold
reduction in activity upon ring size reduction
(22-membered ring) or increasing ~24-membered ring) in
comparison with the optimized ring size (23-membered
ri~g). The conformational constraint of alpha-MSH by
lactam linkage between amino acids in positions S and
10 resulted in a group of cyclic compounds which
comprise a portion of the present invention. The ring
size centered at 23-membered ring, compound 19 qave
the highest biological potency in lizard skin with not
much change in potency in froq skin assay. :The
enhancement in potency between the cyclic and its
linear ancestor is in the order of ten times of
magnitude. The potency of cyclic analogue 18 is not
much affected in comparison to the linear but with one
important change with the appearance of prolonged
activity in the cyclic analogue. The C-terminal
tripeptide, Gly-Pro-Val, has no effect on the potency
of these analogues as is revealed in compound 17.
There is one important factor in these cyclic lactam
peptides, which is the prolongation in activity of the
cyclic in comparison to that found in the linear. The
compounds of the present invention are superior to
alpha-MSH in one or more of the following characteris-
tics: potency as measured by the in vivo and in vitro
D
38 i~
frog and/or lizard assay; duration of in vivo effect
in such assays; and/or resistanc-e to degradation by
blood serum enzymes.
The compounds useful in this invention may be
administered transdermally, and are formulated in
suitable compositions determined by the intended means
of administration, according to methods and procedures
well-known t-o those skilled in the art. As used
throughout this specification, the term "transdermal"
is to be considered in its broadest meaning, that is,
administration a~ross an epithelial layer of cells.
As such, the term is appropriately used to designate
topical, oral, pernasal, and other methods of
administration. For example, the compounds suitable
for use in this invention may be formulated or
compounded with various conventional bases into
preparations such as creams, ointments, gels, lotions,
tablets or sprays depending upon the desired mode of
administration to the individual. In manufacturing
these preparations, the composition may also be mixed
with conventional thickening agents, emollients,
surfactants, pigments, perfumes, preservatives,
fillers, and emuLsifiers, all of which are well known
and conventionally used in the formulation of
transdermal preparations. Typically, these nonactive
ingredients will make up the greater part of the final
preparation. ~'referably, the compositions are
manufactured to allow for slow-release or timed-
release delivery.
The remarkable properties of compounds of the
invention also render them useful as substitutes for
alpha-MSH and [N:Le4]-alpha-MSH in existing diagnostic,
therapeutic and basic research schemes. In the area
of diagnostic peocedures, it i~ apparent that com-
pounds of the invention, especially those which have
been radioio(linated or coupled with gamma radiation
1 ~,6 ~ 7
emitters, ar~ exceptionally wel~ suited for use in
locating and~or differentially characterizing melanoma
cells on the basis of association with melanotropin
receptors in such cells. The serum stability of
compounds of the invention makes them prime candidates
in proposed selective drug ~~elivery systems wherein
target tissues are known to have high concentrations
of melanotropin receptors. The relativt- high potency
and prolonged activity of compounds of the invention
in color chan~e-associated phenomena is expected to be
duplicated in the context of other biological effects
previously nc)ted for naturally occurring melanocyte
stimulating hormone and its synthetic analogues.
Thus, while we have illustrated and described the
preferred emkodiments of our invention, it is to be
understood that t:his invention is capable of variation
and modification, and we therefore do not wish to be
limited to the precise terms set forth, but desire to
avail ourselves of such changes and alterations which
may be made for adapting the invention to various
usages and cc~nditions. Accordingly, such changes and
alterations are properly intended to be within the
full range o~ equivalents, and therefore within the
purview, of the iollowing claims.
Having thus described our invention and the
manner and process of makint~ and usin~ it, in such
full, clear, concise, and exact terms so as to enable
any person skilled in the art to which it pertains, or
with which it is most nearly connected, and to make
and use the same
